Concepedia

Hui Qiu

HQ

Statistics

Publications

6

Citations

243

H-Index

6

Active since

2018

Affiliations

Roche (Switzerland)(Current)

Merck Serono S.p.A. (Italy)

Constellation Pharmaceuticals (United States)

Nanjing Agricultural University

Ono Pharmaceutical (United States)

Hui Qiu is an author at Roche (Switzerland) specializing in enzyme inhibition, drug discovery, and medicinal chemistry.

ORCID

Publications per year

2018–2024

6

Publications

6

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

Richard D. Caldwell, Hui Qiu, Ben Askew et al. · Journal of Medicinal Chemistry · 2019 · 140 citations · Full text

, , +14

Resistance Risk and Molecular Mechanism of Tomato Wilt Pathogen <i>Fusarium oxysporum</i> f. sp. <i>lycopersici</i> to Pyraclostrobin

Yushuai Mao, Hui Qiu, Xinlong Gao et al. · Journal of Agricultural and Food Chemistry · 2024 · 27 citations

, , +15

Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit

Hui Qiu, Lesley Liu‐Bujalski, Richard D. Caldwell et al. · Bioorganic & Medicinal Chemistry Letters · 2018 · 24 citations · Full text

, , +14

Risk assessment and molecular mechanism of Sclerotium rolfsii resistance to boscalid

Hui Qiu, Xianghao Meng, Shengxue Li et al. · Pesticide Biochemistry and Physiology · 2024 · 19 citations

, , +8

Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk

Richard D. Caldwell, Lesley Liu‐Bujalski, Hui Qiu et al. · Bioorganic & Medicinal Chemistry Letters · 2018 · 17 citations · Full text

, , +16

1–5 of 6